20.8 Million Patients Suffer from Diabetic Leg Ulcers, Bed Sores and Surgical Wounds

Wound healing requires angiogenesis for the healing process to occur, making this indication an attractive target for treatment with FGF-1141. In animal models, FGF-1141 has been shown to be a potent stimulator of wound healing, almost doubling the rate at which a wound will heal. People with diminished healing abilities, including diabetics and the elderly, could greatly benefit from an agent that could stimulate the growth of new blood vessels in the wounded area.

In this indication, the drug is applied topically to the wounded area. Our studies have shown that none of the drug enters the circulation when applied topically, a fact that should result in less risk of side effects.


< Back to Treatment Applications

Use of this site constitutes agreement to our Terms and Conditions
and Privacy Policy. Site Design and Contents © 2008 CardioVascular BioTherapeutics, Inc. All Rights Reserved.

Some content on this site requires the free Adobe Reader.